Chemotherapy plus trastuzumab is generally the first-line standard of care in patients with HER2-positive metastatic GC, irrespective of programmed death ligand 1 (PD-L1) expression, with a median overall survival of 13.8 months (Bang et al., 2010). Here, ERBB2 is linked to gastric cancer.